Given the activity of these drugs in cancer treatment research is now focused on investigating in particular oral HER2 and EGFR receptor tyrosine kinase inhibitors in preclinical and early clinical trials as breast cancer-preventive drugs. Here, ERBB2 is linked to breast carcinoma.